Literature DB >> 19857121

Production and characterization of monoclonal antibodies to human sclerostin.

Theodore A Craig1, Stacy L Sommer, Thomas G Beito, Rajiv Kumar.   

Abstract

We developed and characterized monoclonal antibodies directed against the amino-terminal and carboxy-terminal regions of human and mouse sclerostin (scl). Amino-terminal and carboxy-terminal scl peptides with limited homology to scl domain-containing protein-1 were synthesized using f-moc chemistry. The peptides were conjugated to keyhole limpet hemocyanin and the conjugates were used for immunization of mice. Monoclonal antibodies were obtained and characterized using bacterially expressed and insect cell-expressed recombinant scl. The amino-terminal (IgG 2aK) and carboxy-terminal (IgG 2bK) antibodies bound bioactive sclerostin that was expressed in an insect-cell expression system with dissociation constants in the nanomolar range. The antibodies are potentially useful agents that can be used for modulating sclerostin bioactivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857121      PMCID: PMC3145175          DOI: 10.1089/hyb.2009.0036

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  30 in total

1.  Characterization of monoclonal antibodies against the glaucoma-associated protein myocilin.

Authors:  Mohamed-Karim Ezzat; Kyle G Howell; Cindy K Bahler; Thomas G Beito; Nils Loewen; Eric M Poeschla; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-07-12       Impact factor: 3.467

2.  Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method.

Authors:  M H Caruthers; A D Barone; S L Beaucage; D R Dodds; E F Fisher; L J McBride; M Matteucci; Z Stabinsky; J Y Tang
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

Review 3.  Deoxyoligonucleotide synthesis via the phosphoramidite method.

Authors:  M H Caruthers; S L Beaucage; C Becker; J W Efcavitch; E F Fisher; G Galluppi; R Goldman; P deHaseth; M Matteucci; L McBride
Journal:  Gene Amplif Anal       Date:  1983

4.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

Authors:  W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

5.  Biological activity of FGF-23 fragments.

Authors:  Theresa J Berndt; Theodore A Craig; Daniel J McCormick; Beate Lanske; Despina Sitara; Mohammed S Razzaque; Marlon Pragnell; Ann E Bowe; Stephen P O'Brien; Susan C Schiavi; Rajiv Kumar
Journal:  Pflugers Arch       Date:  2007-02-27       Impact factor: 3.657

6.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

7.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.

Authors:  W Balemans; N Patel; M Ebeling; E Van Hul; W Wuyts; C Lacza; M Dioszegi; F G Dikkers; P Hildering; P J Willems; J B G M Verheij; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  J Med Genet       Date:  2002-02       Impact factor: 6.318

8.  Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex.

Authors:  David G Winkler; Changpu Yu; James C Geoghegan; Ethan W Ojala; John E Skonier; Diana Shpektor; May K Sutherland; John A Latham
Journal:  J Biol Chem       Date:  2004-06-14       Impact factor: 5.157

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

View more
  2 in total

1.  The sclerostin-bone protein interactome.

Authors:  Hemamalini Devarajan-Ketha; Theodore A Craig; Benjamin J Madden; H Robert Bergen; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2011-12-22       Impact factor: 3.575

2.  Sclerostin binds and regulates the activity of cysteine-rich protein 61.

Authors:  Theodore A Craig; Resham Bhattacharya; Debabrata Mukhopadhyay; Rajiv Kumar
Journal:  Biochem Biophys Res Commun       Date:  2009-12-31       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.